TITLE

Pharmacological Management of Neuropathic Pain Following Spinal Cord Injury

AUTHOR(S)
Baastrup, Cathrine; Finnerup, Nanna B.
PUB. DATE
April 2008
SOURCE
CNS Drugs;2008, Vol. 22 Issue 6, p455
SOURCE TYPE
Academic Journal
DOC. TYPE
Article
ABSTRACT
Spinal cord injury (SCI) has a number of severe and disabling consequences, including chronic pain, and around 40% of patients develop persistent neuropathic pain. Pain following SCI has a detrimental impact on the patient's quality of life and is a major specific healthcare problem in its own right. Thus far, there is no cure for the pain and oral pharmaceutical intervention is often inadequate, commonly resulting in a reduction of only 20-30% in pain intensity. Neuropathic pain sensations are characterized by spontaneous persistent pain and a range of abnormally evoked responses, e.g. allodynia (pain evoked by normally nonnoxious stimuli) and hyperalgesia (an increased response to noxious stimuli). Neuropathic pain following SCI may be present at or below the level of injury. Oral pharmacological agents used in the treatment of neuropathic pain act either by depressing neuronal activity, by blocking sodium channels or inhibiting calcium channels, by increasing inhibition via GABA agonists, by serotonergic and noradrenergic reuptake inhibition, or by decreasing activation via glutamate receptor inhibition, especially by blocking the NMDA receptor. At present, only ten randomized, double-blind, controlled trials have been performed on oral drug treatment of pain after SCI, the results of most of which were negative. The studies included antidepressants (amitriptyline and trazodone), antiepileptics (gabapentin, pregabalin, lamotrigine and valproate) and mexiletine. Gabapentin, pregabalin and amitriptyline showed a significant reduction in neuropathic pain following SCI. Cannabinoids have been found to relieve other types of central pain, and serotonin noradrenaline reuptake inhibitors as well as opioids relieve peripheral neuropathic pain and may be used to treat patients with SCI pain.
ACCESSION #
33893489

 

Related Articles

  • The Function of FGFR1 Signalling in the Spinal Cord: Therapeutic Approaches Using FGFR1 Ligands after Spinal Cord Injury. Haenzi, Barbara; Moon, Lawrence D. F. // Neural Plasticity;1/18/2017, p1 

    Extensive research is ongoing that concentrates on finding therapies to enhance CNS regeneration after spinal cord injury (SCI) and to cure paralysis. This review sheds light on the role of the FGFR pathway in the injured spinal cord and discusses various therapies that use FGFR activating...

  • Inflammasome: Its role in traumatic brain and spinal cord injury. Mortezaee, Keywan; Khanlarkhani, Neda; Beyer, Cordian; Zendedel, Adib // Journal of Cellular Physiology;Jul2018, Vol. 233 Issue 7, p5160 

    Traumatic brain injury (TBI) and spinal cord injury (SCI) are pathological events that lead to neuropathological conditions which have in consequence the initiation of pro‐inflammatory cytokine production. Neuroinflammation plays a key role in the secondary phase of both TBI and SCI after...

  • LATER MANAGEMENT AND COMPLICATIONS-II. Grundy, David; Russell, John // British Medical Journal (Clinical Research Edition);3/15/1986, Vol. 292 Issue 6522, p743 

    Examines the treatment of patients with spinal cord injuries. Frustrations associated with the physical limitation of a spinal cord injury; Restoration of function in arms by tetraplegics; Factors in selection for surgery.

  • Alvimopan for postoperative ileus. Bream-Rouwenhorst, Heather R.; Cantrell, Matthew A. // American Journal of Health-System Pharmacy;7/15/2009, Vol. 66 Issue 14, p1267 

    Purpose. The efficacy, safety, pharmacology, pharmacokinetics, drug-drug interactions, and administration of alvimopan for postoperative ileus are reviewed. Summary. Alvimopan is a selective μ-opioid receptor antagonist with no central nervous system activity. When orally administered after...

  • Regeneration of Spinal Cord Connectivity Through Stem Cell Transplantation and Biomaterial Scaffolds. Katoh, Hiroyuki; Yokota, Kazuya; Fehlings, Michael G. // Frontiers in Cellular Neuroscience;6/6/2019, pN.PAG 

    Significant progress has been made in the treatment of spinal cord injury (SCI). Advances in post-trauma management and intensive rehabilitation have significantly improved the prognosis of SCI and converted what was once an "ailment not to be treated" into a survivable injury, but the cold hard...

  • Motor neurone excitability in back muscles assessed using mechanically evoked reflexes in spinal cord injured patients. Kuppuswamy, A.; Theodorou, S.; Catley, M.; Strutton, P. H.; Ellaway, P. H.; McGregor, A. H.; Davey, N. J. // Journal of Neurology, Neurosurgery & Psychiatry;Sep2005, Vol. 76 Issue 9, p1259 

    Objective: The clinical and functional assessment of back muscles in human spinal cord injury (SCI) has received little attention. The aim of this study was to develop a method to assess the level of a thoracic spinal cord lesion based on the reflex activation of back...

  • Skiers should consider spine protection to avoid severe injury.  // Nursing Standard;3/12/2008, Vol. 22 Issue 27, p15 

    The article reports on the findings of a research conducted by researchers in Switzerland regarding the epidemiological data, clinical features and mechanisms of several spinal injuries related to alpine skiing and snowboarding. The study showed that central nervous system injuries and transient...

  • Reduction in antioxidant enzyme expression and sustained inflammation enhance tissue damage in the subacute phase of spinal cord contusive injury. Chih-Yen Wang; Jen-Kun Chen; Yi-Ting Wu; May-Jywan Tsai; Song-Kun Shyue; Chung-Shi Yang; Shun-Fen Tzeng // Journal of Biomedical Science;2011, Vol. 18 Issue 1, p13 

    Background: Traumatic spinal cord injury (SCI) forms a disadvantageous microenvironment for tissue repair at the lesion site. To consider an appropriate time window for giving a promising therapeutic treatment for subacute and chronic SCI, global changes of proteins in the injured center at the...

  • Pharmacology and Therapeutics of Gabapentin in the Treatment of Psychiatric Disorders; Present and Future Perspectives. Megna, J. L.; Iqbal, M. M.; Aneja, A. // Current Neuropharmacology;Sep2003, Vol. 1 Issue 3, p187 

    Gabapentin is an antiepileptic drug, which decreases neuronal excitability and may act by increasing the availability of gamma-aminobutyric acid or by inhibiting Ca2+ channels. It has safe pharmacokinetic and side effect profiles. Not surprisingly, it has been tested as a treatment in a number...

Share

Read the Article

Courtesy of THE LIBRARY OF VIRGINIA

Sorry, but this item is not currently available from your library.

Try another library?
Sign out of this library

Other Topics